Gals Bio

Company Overview

Snapshot

Founded in October 2015 by Hilla Shaviv, Gals Bio operates with 1–10 employees. The company has raised $1.96M across two funding rounds from two investors, developing innovative Fem-Wearables for women's health. In January 2022, Gals Bio secured equity crowdfunding from PipelBiz.

Business overview

Gals Bio is a Health Tech & Life Sciences company focused on pioneering Fem-Wearables, a new category in women's health and wellness. The company leverages the unique vaginal environment and integrates AI-powered analysis to provide personalized, early, and accessible home health solutions. These solutions, including their first device Tulipon, are designed for rapid screening, monitoring, and therapeutic care, serving markets across the Americas, Europe, and globally.

Strategic signal

In January 2022, Gals Bio was featured in Haaretz for its innovative approach to femtech, specifically highlighting its new smart tampon. This signals the company's potential to disrupt the women's health market by offering advanced, non-invasive diagnostic tools, attracting attention to its novel Fem-Wearables category and its commitment to early detection and personalized care.

Company Intelligence Q&A

What is Gals Bio's primary focus?

Gals Bio is pioneering a new category in women’s health and wellness called Fem-Wearables, leveraging the unique vaginal environment and AI-powered analysis for personalized home health solutions.

When was Gals Bio founded?

Gals Bio was founded in October 2015 by Hilla Shaviv.

What is Tulipon?

Tulipon is Gals Bio's first device, designed for clean collection of vaginal secretions for cancer screening. It enables women with abnormal bleeding, BRCA mutations, or high cancer risk to use Tulipon for up to 12 hours to collect samples for AI-powered liquid biopsy analysis, minimizing human interference and contamination.

What markets does Gals Bio serve?

Gals Bio serves global markets, including the Americas and Europe, with its women's health solutions.